22 completed, 11 recruiting, 11 terminated, 10 active not recruiting. 38 Phase 2, 23 Phase 1, 7 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow OPDIVO®: new trials by email Literature Review of OPDIVO® trials Research Report on OPDIVO®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors HLX18, OPDIVO® - Esophageal and/or Cardia Cancer, Melanoma | Phase 1 | Recruiting | Shanghai Henlius Biotech | 174 | 2026-07-15 | 2026-07-27 |
| Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib - Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma | Phase 2 | Recruiting | CatalYm GmbH | 104 | 2026-03-19 | 2026-09-23 |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer ONO-4578, Opdivo®, Oxaliplatin - Colorectal Cancer | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 144 | 2025-11-18 | 2026-07-16 |
| Patient Preference for Subcutaneous vs. Intravenous Immune Therapy nivolumab, pembrolizumab - Renal Cell Carcinoma, Non Small Cell Lung Cancer | Phase 2 | Recruiting | Diwakar Davar | 880 | 2025-11-04 | 2026-04-16 |
| Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Recruiting | CatalYm GmbH | 131 | 2025-10-07 | 2026-08-19 |
| Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi Single agent, adjuvant anti-PD1 therapy - Melanoma | Recruiting | John Kirkwood | 30 | 2025-02-20 | 2026-01-26 | |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) zanzalintinib, AB521, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Phase 1 | Terminated | Exelixis | 25 | 2024-01-25 | 2025-06-12 |
| A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma ABP 206, Nivolumab - Melanoma | Phase 3 | Active not recruiting | Amgen | 633 | 2023-11-02 | 2026-01-12 |
| A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma LY01015, Fluorouracil, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | Shandong Boan Biotechnology Co., Ltd | 510 | 2023-10-12 | 2026-10-13 |
| A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab - Melanoma | Phase 3 | Completed | Amgen | 256 | 2023-07-26 | 2026-03-27 |
| A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors BMS-986449, Nivolumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 100 | 2023-06-06 | 2025-06-11 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors BMS-986360, Docetaxel, Nivolumab - Advanced Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 70 | 2022-12-09 | 2025-06-13 |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors SAR445877, Cetuximab, ADG126 - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Sanofi | 542 | 2022-11-29 | 2026-06-23 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Pixatimod, Nivolumab, Cyclophosphamide (low dose) - NSCLC, Metastatic Colorectal Carcinoma | Phase 2 | Completed | Diwakar Davar | 13 | 2021-12-09 | 2026-09-08 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
| Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. Nivolumab, Ipilimumab, Influenza vaccine - Pancreatic Cancer | Phase 2 | Terminated | Herlev Hospital | 19 | 2021-11-05 | 2024-05-28 |
| Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) Tenofovir Alafenamide, VIR-2218, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 103 | 2021-08-14 | 2025-07-24 |
Showing 20 of 57. Sign in to see all of them.
Melanoma (16) · Carcinoma, Renal Cell (7) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (5) · Pancreatic Neoplasms (5) · Carcinoma, Transitional Cell (4) · Colorectal Neoplasms (4) · Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Hepatocellular (3) · Kidney Neoplasms (3) · Recurrence (3) · Esophageal Squamous Cell Carcinoma (2) · Glioma (2) · Head and Neck Neoplasms (2)
Nektar Therapeutics (5) · Herlev Hospital (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Amgen (2) · Bristol-Myers Squibb (2) · CatalYm GmbH (2) · Dana-Farber Cancer Institute (2) · Diwakar Davar (2) · Exelixis (2) · Immatics US, Inc. (2) · AbbVie (1) · Aravive, Inc. (1) · Bradley A. McGregor, MD (1) · Case Comprehensive Cancer Center (1) · Daiichi Sankyo (1)
United States (46) · Spain (17) · Italy (15) · France (14) · Germany (11) · United Kingdom (10) · Netherlands (9) · Canada (8) · Argentina (7) · Australia (7) · Chile (6) · Czechia (6) · Denmark (6) · South Korea (6) · Brazil (5)
Cedrik Britten, M.D. (2) · Inna M Chen, MD (2) · Bradley McGregor, MD (1) · Dan Zandberg, MD (1) · Diwakar Davar, MD (1) · Diwakar J Davar, MD (1) · Fabio Iwamoto, MD (1) · Farshid Dayyani, MD, PhD (1)
PMID 42836590, PMID 28062705, PMID 31097024, PMID 32651467, PMID 33544407, PMID 34253597, PMID 34599023, PMID 35073733, PMID 35444059, PMID 35476508, PMID 36592507, PMID 36634920, PMID 37507657, PMID 37744345, PMID 37783966, PMID 37864885, PMID 38838287, PMID 39208489, PMID 39325832, PMID 40008409, PMID 40205198, PMID 40549043, PMID 40844778, PMID 41824279
2023 (4), 2018 (3), 2017 (2), 2015 (1), 2016 (1), 2019 (1), 2025 (1)